[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"total-gastrectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:total-gastrectomy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100590450","reconstruction-with-a-lawrence-hunt-jejunal-pouch-after-total-gastrectomy-100590450",false,"NCT06967571","Reconstruction With a Lawrence-Hunt Jejunal Pouch After Total Gastrectomy","Reconstruction With a Lawrence-Hunt Jejunal Pouch for Upfront Total Gastrectomy - Study Protocol of a Prospective, Single-arm, Phase II Trial","REJOY","Inclusion Criteria:\n\n* Adults aged 18-75 years.\n* Histologically confirmed gastric tumor (including adenocarcinoma, gastrointestinal stromal tumor - GIST- or neuroendocrine tumor) or patients with CDH1 mutation, scheduled for TG with a maximal esophageal resection of \\\u003C 6 cm.\n* Informed consent capability.\n\nExclusion Criteria:\n\n* Prior abdominal surgeries affecting the jejunum.\n* Severe comorbidities or non-appropriate organ function: uncontrolled diabetes with HbA1C \\> 7.5, significant heart disease: New York Heart Association (NYHA) functional classification Class III or IV, chronic obstructive pulmonary disease (COPD) requiring oxygen supplementation or continuous positive airway pressure (CPAP), chronic corticosteroid therapy (daily for more than 6 months), neutrophil count \\\u003C 2000\u002Fmm3, hemoglobin \\\u003C 8.0 g\u002FdL, platelet count \\\u003C 100,000\u002Fmm3, serum total bilirubin \\> 1.5 mg\u002FdL, serum aspartate aminotransferase (AST) \\>100 IU\u002FL, serum alanine aminotransferase (ALT) \\>100 IU\u002FL, and creatinine clearance (CCr) ≥ 50 mL\u002Fmin), ECOG performance status \\> 1.\n* Pregnancy or breastfeeding.","ALL","18 Years","75 Years",{"count":21,"type":22},26,"ESTIMATED","INTERVENTIONAL",[25],"NA","The aim of the study is to establish the efficacy of jejunal pouch reconstruction in reducing dumping syndrome in patients undergoing total gastrectomy, ultimately enhancing postoperative quality of life and nutritional status.",[28,29],"Total Gastrectomy","Gastric Cancer",[31,32],"gastric cancer","total gastrectomy","RECRUITING","2026-07-22",{"date":36,"type":37},"2026-07-23","ACTUAL",{"date":39,"type":37},"2026-01-01",{"date":41,"type":22},"2028-04-01",{"name":43,"class":44},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100552121","enhanced-vs-routine-follow-up-after-total-gastrectomy-for-advanced-gastric-cancer-a-randomized-controlled-trial-100552121","NCT06468969","Enhanced vs. Routine Follow-Up After Total Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial","A Prospective, Single-Center, Randomized Controlled Trial Comparing Enhanced Follow-up With Standard Follow-up in Post-Gastrectomy Patients With Advanced Gastric Cancer","Inclusion Criteria:\n\n* Age: 18 to 72 years at the time of informed consent.\n* Underwent radical total gastrectomy.\n* Postoperative pathology confirmed advanced adenocarcinoma of the stomach or gastroesophageal junction.\n* Estimated survival time ≥3 months.\n* Good cognitive and reading abilities, capable of completing questionnaires.\n* Willing and able to provide written informed consent for the study.\n\nExclusion Criteria:\n\n* Participation in another clinical trial within 4 weeks prior to enrollment.\n* Patients with other malignancies.\n* Clinically significant cardiovascular disease, such as heart failure (NYHA III-IV), uncontrolled coronary artery disease, cardiomyopathy, arrhythmia, or hypertension.\n* Neurological or psychiatric disorders affecting cognitive function, including central nervous system metastasis.\n* Active infectious diseases, such as active hepatitis or tuberculosis.\n* Uncontrolled systemic diseases, such as poorly controlled diabetes.\n* Interstitial lung disease, such as interstitial pneumonia, pulmonary fibrosis, or evidence of interstitial lung disease on baseline chest X-ray\u002FCT.\n* Pregnant or breastfeeding.","72 Years",{"count":55,"type":22},158,[25],"The goal of this clinical trial is to compare the effectiveness of enhanced follow-up with standard follow-up in postoperative patients with advanced gastric cancer who have undergone radical gastrectomy. The main questions it aims to answer are:\n\nCan enhanced follow-up alleviate symptom burden and improve quality of life? What is the impact of enhanced follow-up on overall survival rates at 3 and 5 years post-surgery?\n\nParticipants will:\n\nBe randomly assigned to either the enhanced follow-up group or the standard follow-up group.\n\nUndergo comprehensive symptom, nutritional, and psychological assessments every 3 weeks (enhanced follow-up group).\n\nReceive routine postoperative follow-up including medical examinations and treatments as needed, with additional assessments only when necessary (standard follow-up group).\n\nResearchers will compare the enhanced follow-up group with the standard follow-up group to see if enhanced follow-up can improve quality of life and increase overall survival rates at 3 and 5 years post-surgery.\n\nOutcomes will be measured using the EORTC QLQ-C30 quality of life questionnaire and overall survival rates. This prospective, single-center, randomized controlled clinical trial will span 5 years from the approval by the institutional ethics committee and will include 158 patients.",[29,28,59,60,61],"Postoperative Care","Quality of Life","Follow-up","NOT_YET_RECRUITING","2024-06-16",{"date":65,"type":37},"2024-06-21",{"date":67,"type":22},"2024-07-01",{"date":69,"type":22},"2029-07-01",{"name":71,"class":44},"Fudan University"]